Acute nitrous oxide‐induced neuropathy mimicking Guillain‐Barré syndrome
- 7 June 2022
- journal article
- research article
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 27 (3) , 189-196
Abstract
The early clinical features of nitrous oxide (N2O)‐induced neuropathy were mimicking that of Guillain‐Barré syndrome (GBS). We aimed to explore clinical and laboratory characteristics of N2O‐induced neuropathy in comparison with GBS. We retrospectively reviewed data of 15 patients with N2O‐induced neuropathy and compared them with 15 GBS patients. The age of the N2O‐induced neuropathy group was significantly younger than that in the GBS group (22 ± 5 vs 45 ± 17). Paresthesia was more common in N2O‐induced neuropathy group (100% vs 53.3%). The proportion of distal upper limbs weakness was lower than that in GBS group (20.0% vs 93.3%). There was no significant difference in the distal weakness of the lower limbs (100% vs 80.0%). The incidence of motor conduction block and compound muscle action potential amplitude reduction in upper limbs was lower than that in GBS group (6.7% vs 60.0%; 26.7% vs 80.0%). The sensory nerve action potential amplitude drop in the lower limbs was more severe than that in GBS group (53.3% vs 0). The increase of Mean corpuscular volume (MCV) was more pronounced compared to GBS group (96.97 ± 6.00 vs 88.55 ± 5.41). High homocysteine levels were more common in N2O‐related group [29.80(11.60, 70.50) vs 14.35(9.22, 19.30)]. Typical clinical features of the acute N2O neuropathy appears to be a myeloneuropathy, affecting the lower limbs more than the upper limbs, mixed axonal‐demyelinating electrophysiological performance, higher homocysteine level, and larger MCV and common posterior spinal cord involvement in cervical segment.Keywords
Funding Information
- Key Research and Development Projects of Shaanxi Province (2019SF‐227)
This publication has 30 references indexed in Scilit:
- Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept TrialBiological Psychiatry, 2015
- Diagnosis of Guillain-Barre syndrome and validation of Brighton criteriaBrain, 2013
- Biologic Effects of Nitrous OxideAnesthesiology, 2008
- Vitamin B12, folic acid, and the nervous systemThe Lancet Neurology, 2006
- A modified peripheral neuropathy scale: the Overall Neuropathy Limitations ScaleJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathyClinical Neurophysiology, 2004
- Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxinNature Medicine, 1998
- Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndromeMuscle & Nerve, 1991
- Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocysteine and folate in plasma and urineClinical Pharmacology & Therapeutics, 1991
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990